DENVER — SeaStar Medical Holding Corporation (Nasdaq: ICU) announced Wednesday that new clinical data validating the efficacy of its flagship pediatric therapy will take center stage at the upcoming American Society of Nephrology (ASN) Kidney Week 2026. The company has been selected for a special late-breaking poster presentation on October 22 in Denver, Colorado, highlighting significant advancements in the treatment of pediatric patients suffering from sepsis-associated acute kidney injury (AKI).
The presentation, titled “Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of the Selective Cytopheretic Device for Pediatrics (SCD-PED) Surveillance Registry (SAVE) with a Historical Cohort,” provides a detailed analysis of the post-approval SAVE Registry data. By comparing real-world outcomes from the SCD-PED—marketed as QUELIMMUNE—against historical data, the research aims to quantify the clinical benefits of the device for critically ill children. The study features an extensive list of contributors, including lead researchers such as Stuart Goldstein and Rajit K. Basu.
QUELIMMUNE, which received FDA approval in 2024, remains the only therapeutic option specifically cleared for life-threatening AKI in pediatric patients requiring renal replacement therapy. The device utilizes Selective Cytopheretic Device (SCD) technology to address the underlying physiological triggers of organ failure, offering a targeted intervention for a condition that has historically lacked effective, specialized treatment options.
“This selection for a late-breaking presentation at Kidney Week underscores the clinical significance of our work in the pediatric space,” a spokesperson for SeaStar Medical noted. “The SAVE Registry data provides a critical window into the real-world impact of QUELIMMUNE, demonstrating our commitment to improving survival rates for the most vulnerable patients.”
The presentation is scheduled for October 22, 2026, from 10:00 a.m. to 12:00 p.m. MT in Exhibit Hall A of the Colorado Convention Center.
Beyond its pediatric applications, SeaStar Medical is aggressively expanding its clinical footprint. The company’s SCD technology has been awarded Breakthrough Device Designation for six separate therapeutic indications, reflecting its potential to address high-unmet needs in the intensive care unit. Currently, the company is conducting the NEUTRALIZE-AKI pivotal clinical trial, which evaluates the device’s efficacy in adult patients suffering from AKI requiring continuous renal replacement therapy. This condition affects more than 200,000 adults in the United States annually and is frequently associated with high mortality rates.
As SeaStar Medical continues its transition from a clinical-stage entity to a commercial powerhouse, the data being presented at ASN Kidney Week is expected to play a vital role in reinforcing the medical community’s confidence in the SCD platform. The conference, which draws global experts in nephrology, serves as a high-profile platform for the company to showcase its progress in revolutionizing care for patients facing organ failure.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
